Bioteque Corporation is a medical device manufacturer specializing in the development and production of hemodialysis consumables, intravascular treatment materials, and other medical supplies. The company manufactures a full range of TPU (thermoplastic polyurethane) indwelling catheters, including pigtail drainage catheter sets, double-J ureteral drainage catheter sets, percutaneous transhepatic biliary drainage catheters, percutaneous nephrostomy drainage catheter sets, and hemodialysis catheter sets. Its intravascular interventional radiology product line includes vascular dilation balloon catheters, vascular angiography catheters, guiding sheaths, CT/MRI contrast injection syringe sets, microcatheters, and hydrophilic guidewires. Bioteque operates manufacturing facilities in Taiwan and the Philippines and provides contract development and manufacturing organization (CDMO) services. The company holds patents covering various medical applications and collaborates with research institutions for new product development. Founded in 1991, Bioteque was listed on the OTC market in 2002.
More
Summarised from the company's own disclosures, fiscal year ended Oct 2026
Industry
Medical Devices
Homepage
bioteq.com.tw/zh-tw
Sector
Healthcare
IR page
bioteq.com.tw/zh-tw/page-categories/investors
Tags
hemodialysis, catheters, interventional radiology, tpu, cdmo, medical consumables, BIOTEQUE
More
Press page
—
Metrics
Market cap
NT$ 7.277B
Market cap (USD)
$ 220.863M
P/E
12.00
PEG
4.01
P/BV
1.98
P/S
3.19
P/OCF
10.36
P/FCF
—
Dividend yield
—
Turnover / mcap
—
ROE
15.3%
ROI
14.9%
ROIC
14.9%
Profit margin
25.2%
Revenue growing
Yes
Profits growing
Yes
Revenue up 3y
No
Revenue up 5y
No
Earnings growth 3y (net profit CAGR)
3.0%
Profitable
Yes
Margin expanding
Yes
Buying back stock
No
Diluting (TTM)
No
Debt/Equity
—
Podcast bulls (TTM)
Sign up
Podcast bears (TTM)
Sign up
Podcast sentiment (TTM)
Sign up
Podcast sentiment % (TTM)
Sign up
News sentiment (TTM)
0
Quality score
37.5%
Buys, 1w
Sign up
Buys, 1m
Sign up
Buys, 1y
Sign up
Sells, 1w
Sign up
Sells, 1m
Sign up
Sells, 1y
Sign up
Sign up to see this company's insider trades
Fundamentals
(all numbers in TWD)
Compare
All 27 figures
Annual
Quarterly
Compare with
×
Revenue
2.135B
2.073B
1.945B
2.01B
1.825B
1.948B
1.859B
1.613B
1.42B
1.407B
1.259B
1.124B
957.883M
842.308M
760.314M
821.623M
Net profit
539.185M
528.26M
452.55M
493.54M
431.257M
488.665M
464.172M
404.997M
303.939M
358.232M
315.766M
290.902M
215.224M
166.308M
128.597M
172.587M
Share price
120.5
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
P/S
3.91
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Sign up to see institutional holdings
Sign Up
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up
Material information published on MOPS, newest first, subjects as filed in Chinese, guarantee and loan balance notices and routine equipment purchases included. The link opens the company's material information on MOPS.
AI comment
This is a routine regulatory filing of the third-quarter consolidated financial report for the period ending September 30, 2026. It does not contain new forward-looking guidance, major contract announcements, or unexpected operational shifts that would alter the company's valuation beyond the standard quarterly update.
AI comment
This is a routine notice regarding the company's invitation to attend an online investor relations meeting hosted by a securities firm. It provides logistical details (date, time, platform) but contains no new financial data, strategic announcements, or operational updates that would impact company value.
AI comment
The company announced the signing of a supplementary order for auxiliary equipment related to its medicinal soft bag production line, valued at 28.14 million TWD. This is a routine capital expenditure to expand capacity, which is slightly positive but immaterial relative to the company's scale (revenue ~2.1B TWD).
AI comment
This is a routine regulatory filing confirming shareholder approval to lift the non-compete restrictions for specific directors under Company Law. It is a standard corporate governance formality with no impact on the company's financial value or operations.
AI comment
This is a routine filing of the resolutions from the Annual General Meeting, including the approval of financial statements and charter amendments. These are standard formalities that do not convey new information about the company's value or performance.
AI comment
This is a routine administrative correction to the date of an upcoming investor relations event (changing the date from May 12 to May 18). It provides no new information regarding the company's financial performance, operations, or value.
AI comment
This is a routine notice informing investors that the company was invited to attend an online investor relations event hosted by a securities firm. It provides logistical details (Webex ID, password) but contains no new financial data, strategic updates, or operational news that would impact company value.
2026-05-12
本公司資安主管異動
Bull 0
Bear 0
Management
AI comment
The company announced a routine change in its Chief Information Security Officer (CISO), with the incumbent resigning and a successor pending board approval. This is a standard personnel filing with no indication of controversy or impact on value.
2026-05-08
本公司會計主管異動
Bull 0
Bear 0
Management
AI comment
Routine filing announcing the appointment of a new accounting supervisor. This is a standard management change with no indication of controversy or impact on value.
AI comment
The company announced a cash dividend of TWD 5.5 per share, totaling approximately TWD 381 million, which represents a modest return of capital and signals financial stability, warranting a minor bullish score.
AI comment
This is a routine regulatory filing of the first quarter consolidated financial report. While it provides data, the event type is a standard periodic disclosure without specific new strategic developments or surprises that would independently drive valuation changes beyond the numbers themselves.
AI comment
This is a routine notice correcting the details of the upcoming Annual General Meeting (AGM), including the date, location, and electronic voting procedures. It contains no new financial or operational information that would impact the company's value.
AI comment
Routine filing announcing the resignation of the accounting supervisor (Lin Yu-jin) and a pending appointment. This is a standard personnel change with no indication of distress or strategic impact.
2026-03-05
董事會決議股利分派
Bull 3
Bear 0
Capital return
AI comment
The board approved a cash dividend of TWD 5.50 per share for FY2024, totaling approximately TWD 381 million. This represents a clear return of capital to shareholders and is a positive signal of financial health, warranting a modest bullish score.
AI comment
This is a routine filing of the annual financial report for the year ended 2024-12-31. While it confirms net profit of 539.185M TWD (up from 452.55M TWD in FY2023), the event type is a standard regulatory disclosure of already reported figures rather than a new earnings surprise or guidance update. Routine filings of this nature are scored 0.
AI comment
This is a routine filing of the annual financial report for the fiscal year ended December 31, 2025. It serves as a formal notice and does not contain new forward-looking guidance or unexpected developments that would alter investor valuation beyond the reported figures.
AI comment
This is a routine notice announcing the date, location, and agenda for the company's annual general meeting. It does not contain any new information regarding financial performance, strategic changes, or material contracts that would impact valuation.
AI comment
The company's subsidiary announced the completion of a self-land entrusted construction contract for a warehouse valued at TWD 122 million. This is a minor capital expenditure intended to improve operational efficiency and supply chain management, representing a small fraction of the company's revenue and equity, and thus has a negligible positive impact on value.
Show all 20 news items
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat.
Shared by
Asian Century Stocks and
Uncovered Thai Stocks .
Thank you.
Base
Enforce Recency
Overview
Bull Bear
Competitive Advantages
Supply Chain
Segments
Earnings Results
Earnings Calls
Management
Stock Price Analysis
Comps
Forward Projection
Red Flags
Management Questions
Devils Advocate
Constraints
Share Value Compliance
Equity Research
Bioteque Corporation (ticker 4107.TWO), listed in Taiwan.
Copy
Clear
Copied
ETFs Holding Bioteque Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
DEXC
0.00%
3,000
$ 9,645.28
Nov 12, 2026
DFEV
0.00%
23,000
$ 73.947K
Nov 12, 2026
DFEM
0.00%
70,000
$ 225.056K
Nov 12, 2026
DFSE
0.00%
3,000
$ 9,645.28
Nov 12, 2026
DFAE
0.00%
30,000
$ 96.453K
Nov 12, 2026
DFAX
0.00%
36,000
$ 115.743K
Nov 12, 2026
AVEM
0.00%
27,000
$ 85.5K
Nov 16, 2026
AVES
0.00%
1,000
$ 3,166.66
Nov 16, 2026
AVSE
0.00%
1,000
$ 3,166.66
Nov 16, 2026
AVEE
0.00%
1,000
$ 3,166.66
Nov 16, 2026